gms | German Medical Science

69. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC)
Joint Meeting mit der Mexikanischen und Kolumbianischen Gesellschaft für Neurochirurgie

Deutsche Gesellschaft für Neurochirurgie (DGNC) e. V.

03.06. - 06.06.2018, Münster

Article

Send article

SSTR-2 as a potential tumor-specific marker for fluorescence guided meningioma surgery

Meeting Abstract

Search Medline for

  • Arash Motekallemi - Universitätsklinikum Münster, Klinik für Neurochirurgie, Münster, Deutschland
  • Bianca Dijkstra - University Medical Center, Neurosurgery, Groningen, Niederlande
  • Hanne-Rinck (JR) Jeltema - University Medical Center, Neurosurgery, Groningen, Niederlande
  • Wilfred F. A. den Dunnen - University Medical Center, Pathology, Groningen, Niederlande
  • Frank A. E. Kruyt - University Medical Center, Medical Oncology, Groningen, Niederlande
  • Rob J. M. Groen - University Medical Center, Neurosurgery, Groningen, Niederlande

Deutsche Gesellschaft für Neurochirurgie. 69. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC), Joint Meeting mit der Mexikanischen und Kolumbianischen Gesellschaft für Neurochirurgie. Münster, 03.-06.06.2018. Düsseldorf: German Medical Science GMS Publishing House; 2018. DocV221

doi: 10.3205/18dgnc225, urn:nbn:de:0183-18dgnc2252

Published: June 18, 2018

© 2018 Motekallemi et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 License. See license information at http://creativecommons.org/licenses/by/4.0/.

Outline

Text

Objective: Meningiomas are the most frequently occurring primary brain tumors in adults. Surgical removal can only be curative with complete resection of the tumor. Several intraoperative techniques have been developed to improve surgical resection, including targeted intraoperative fluorescence guided imaging. To identify the most promising biomarker for intra-operative fluorescence guided meningioma surgery was the aim of this study.

Methods: 148 meningioma specimens representing all meningioma grades were analyzed using immunohistochemistry (IHC) on tissue microarrays (TMAs) to determine expression patterns of meningioma biomarkers epithelial membrane antigen (EMA), platelet derived growth factor β (PDGF-β), vascular endothelial growth factor α (VEGF-α), and somatostatin receptor type 2 (SSTR-2). Subsequently, the most promising biomarker was selected based on Target Selection Criteria (TASC). Marker expression was examined by IHC in 3D cell culture models generated from freshly resected tumor material.

Results: TMA-IHC showed strongest staining for SSTR-2. All cases were positive, with 30.4% moderate/diffuse and 51.4% strong/diffuse staining patterns. TASC analysis showed that SSTR-2 was the most promising target for fluorescence guided imaging, with a total score of 21 (out of 22). Eleven meningioma cultures, which could be maintained for several weeks, were generated. In three cultures, SSTR-2 expression was examined and confirmed in two cases.

Conclusion: SSTR-2 expression was highly sensitive and specific in all 148 meningiomas, regardless of the WHO grade. According to TASC analysis, SSTR-2 is the best target. After establishing in vitro meningioma models with a success rate of 50%, SSTR-2 cell membrane expression was confirmed in two of three meningioma cultures as well. Our findings indicate that SSTR-2 is a promising target for the further development of targeted fluorescence guided meningioma surgery.

Figure 1[Fig. 1], Figure 2 [Fig. 2]